Vaxcyte (5VA) Price & Analysis

Compare

2 Followers

5VA Stock Chart & Stats

€34.80

€2.00(2.45%)

At close: Jan 08 4:00 PM EST

€34.80

€2.00(2.45%)

Day’s Range― - ―

52-Week Range€24.60 - €98.50

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€4.57B

Enterprise Value€3.28B

Total Cash (Recent Filing)€1.71B

Total Debt (Recent Filing)€84.44M

Price to Earnings (P/E)―

Beta1.42

Next Earnings

Mar 02, 2026

EPS Estimate

-1.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.35

Shares Outstanding130,906,270

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio2.62

Price to Book (P/B)3.02

Price to Sales (P/S)0.00

P/FCF Ratio-21.02

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€78.08

Price Target Upside124.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cash ReservesThe 3Q25 cash balance of $2.67B provides runway to mid-2028.

Market PotentialVAX-31 in adults should lead to robust immunogenicity and protection, resulting in a large market.

Vaccine DevelopmentFDA discussions on the VAX-31 pivotal in adults have led to agreement on a non-inferiority study to start in December.

Bears Say

Market ReactionPCVX will trade down in reaction to the extended timelines.

Study Initiation DelaysThe company now plans to initiate the first VAX-31 adult Ph3 study in 4Q25, a delay versus the previously communicated mid-2025 start.

Trial DelaysThe addition of a new optimized dose to the VAX-31 infant Ph2 should benefit efficacy but will delay the trial completion to 'by the end of 1H27.'

Vaxcyte News

Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)

Cash, cash equivalents and investments were $2.67B as of September 30, 2025, compared to $3.135B as of December...

3d ago

PCVX

Vaxcyte price target lowered to $85 from $160 at BTIG

BTIG analyst Thomas Shrader lowered the firm’s price target on Vaxcyte (PCVX) to $85 from $160 and keeps...

23d ago

PCVX

Vaxcyte, Inc. Reports Q3 2025 Financial Results

Vaxcyte, Inc. ( ($PCVX) ) has released its Q3 earnings. Here is a breakdown of the information Vaxcyte,...

3d ago

PCVX

Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte

Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Vaxcyte, retaining the price target of $50.00....

3d ago

PCVX

Vaxcyte’s VAX-31 Study: A Potential Game-Changer in Infant Vaccination

Vaxcyte, Inc. (($PCVX)) announced an update on their ongoing clinical study. Vaxcyte, Inc. is conducting a Phase 2...

11d ago

PCVX

Vaxcyte Signs 15-Year Agreement with Patheon

An update from Vaxcyte ( ($PCVX) ) is now available. On September 24, 2025, Vaxcyte, Inc. entered into...

1M ago

PCVX

Vaxcyte to establish fill-finish manufacturing in North Carolina

Vaxcyte (PCVX) announced a new agreement with Thermo Fisher Scientific (TMO) to bring additional fill-finish commercial manufacturing for...

1M ago

TMO

PCVX

Vaxcyte initiated with a Neutral at Goldman Sachs

Goldman Sachs initiated coverage of Vaxcyte (PCVX) with a Neutral rating and $38 price target The firm believes...

2M ago

PCVX

Vaxcyte advances VAX-31 infant Phase 2 study

Vaxcyte (PCVX) announced advancement of the modified VAX-31 infant Phase 2 randomized, dose-finding study to the third and...

2M ago

PCVX

Vaxcyte Reports Progress in Vaccine Development

Vaxcyte, Inc. ( ($PCVX) ) has released its Q2 earnings. Here is a breakdown of the information Vaxcyte,...

3M ago

PCVX

Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating

Leerink Partners analyst David Risinger has maintained their bullish stance on PCVX stock, giving a Buy rating yesterday....

3M ago

PCVX

Vaxcyte price target lowered to $50 from $85 at TD Cowen

TD Cowen analyst Tara Bancroft lowered the firm’s price target on Vaxcyte (PCVX) to $50 from $85 and...

3M ago

PCVX

Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating

Joseph Stringer, an analyst from Needham, reiterated the Buy rating on Vaxcyte. The associated price target remains the...

3M ago

PCVX

Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Vaxcyte, with a...

3M ago

PCVX

5VA FAQ

What was Vaxcyte, Inc.’s price range in the past 12 months?

Vaxcyte, Inc. lowest stock price was €24.60 and its highest was €98.50 in the past 12 months.

What is Vaxcyte, Inc.’s market cap?

Vaxcyte, Inc.’s market cap is €4.57B.

When is Vaxcyte, Inc.’s upcoming earnings report date?

Vaxcyte, Inc.’s upcoming earnings report date is Mar 02, 2026 which is in 114 days.

How were Vaxcyte, Inc.’s earnings last quarter?

Vaxcyte, Inc. released its earnings results on Nov 04, 2025. The company reported -€1.352 earnings per share for the quarter, missing the consensus estimate of -€1.073 by -€0.279.

Is Vaxcyte, Inc. overvalued?

According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vaxcyte, Inc. pay dividends?

Vaxcyte, Inc. does not currently pay dividends.

What is Vaxcyte, Inc.’s EPS estimate?

Vaxcyte, Inc.’s EPS estimate is -1.3.

How many shares outstanding does Vaxcyte, Inc. have?

Vaxcyte, Inc. has 130,906,270 shares outstanding.

What happened to Vaxcyte, Inc.’s price movement after its last earnings report?

Vaxcyte, Inc. reported an EPS of -€1.352 in its last earnings report, missing expectations of -€1.073. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Vaxcyte, Inc.?

Currently, no hedge funds are holding shares in DE:5VA

Vaxcyte Stock Smart Score

Underperform

Fundamentals

Return on Equity

-20.83%

Trailing 12-Months

Asset Growth

-10.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte (5VA) Earnings & Revenues

Historic Earnings Reports

5VA Stock 12 Month Forecast

Average Price Target

€78.08

▲(124.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"€23","82":"€82","141":"€141","52.5":"€52.5","111.5":"€111.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140.88913965,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€140.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.0767851815,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€78.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.8453209,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€32.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,52.5,82,111.5,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37,44.99147228076923,52.98294456153846,60.97441684230769,68.96588912307692,76.95736140384616,84.94883368461538,92.94030596538462,100.93177824615384,108.92325052692308,116.91472280769231,124.90619508846154,132.89766736923076,{"y":140.88913965,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37,40.15975270626923,43.31950541253846,46.47925811880769,49.63901082507692,52.798763531346154,55.958516237615385,59.118268943884615,62.278021650153846,65.43777435642308,68.59752706269231,71.75727976896154,74.91703247523077,{"y":78.0767851815,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37,36.6804093,36.3608186,36.0412279,35.721637199999996,35.4020465,35.0824558,34.7628651,34.4432744,34.1236837,33.804092999999995,33.484502299999996,33.164911599999996,{"y":32.8453209,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":101,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >